HSR21-057: Cost-Effectiveness of Cemiplimab vs Pembrolizumab for the First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (aNSCLC) and Programmed Death-Ligand 1 (PD-L1) Expression ≥50% in the US
Journal of The National Comprehensive Cancer Network（2021）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要